The DOI matches its Crossref record; 244 of the 244 references it cites were found in a registry or an index.
Idiopathic Pulmonary Fibrosis and Lung Cancer: Mechanisms and Molecular Targets
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) is the most common idiopathic interstitial pulmonary disease with a median survival of 2–4 years after diagnosis. A significant number of IPF patients have risk factors, such as a history of smoking or concomitant emphysema, both of which can predispose the patient to lung cancer (LC) (mostly non-small cell lung cancer (NSCLC)). In fact, IPF itself increases the risk of LC development by 7% to 20%. In this regard, there are multiple common genetic, molecular, and cellular processes that connect lung fibrosis with LC, such as myofibroblast/mesenchymal transition, myofibroblast activation and uncontrolled proliferation, endoplasmic reticulum stress, alterations of growth factors expression, oxidative stress, and large genetic and epigenetic variations that can predispose the patient to develop IPF and LC. The current approved IPF therapies, pirfenidone and nintedanib, are also active in LC. In fact, nintedanib is approved as a second line treatment in NSCLC, and pirfenidone has shown anti-neoplastic effects in preclinical studies. In this review, we focus on the current knowledge on the mechanisms implicated in the development of LC in patients with IPF as well as in current IPF and LC-IPF candidate therapies based on novel molecular advances.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–244 of 244
Superoxide scavenging activity of pirfenidone–iron complex
Mitani, Y., Sato, K., Muramoto, Y., Karakawa, T., Kitamado, M., Iwanaga, T., Nabeshima, T., Maruyama, K., Nakagawa, K., Ishida, K., et al. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.04.093 · Cited by 65
The Autotaxin—Lysophosphatidic Acid Axis Promotes Lung Carcinogenesis
Magkrioti, C., Oikonomou, N., Kaffe, E., Mouratis, M.-A., Xylourgidis, N., Barbayianni, I., Megadoukas, P., Harokopos, V., Valavanis, C., Chun, J. J. M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-3797 · Cited by 65
Lung Cancer in Pulmonary Fibrosis: Tales of Epithelial Cell Plasticity
Königshoff, M. (2011) · Respiration · doi:10.1159/000326299 · Cited by 63
Guyard, A., Danel, C. J., Théou–Anton, N., Debray, M., Gibault, L., Mordant, P., Castier, Y., Crestani, B., Zalcman, G., Blons, H., et al. (2017) · Respiratory Research · doi:10.1186/s12931-017-0605-y · Cited by 63
Yu, C., Yang, P., Shun, C., Lee, Y.-C., Kuo, S.-H., & Luh, K. (1996) · International Journal of Cancer · Cited by 62
Role of tetrahydrobiopterin in pulmonary vascular remodelling associated with pulmonary fibrosis
Almudéver, P., Milara, J., Diego, A. D., Serrano‐Mollar, A., Xaubet, A., Pérez‐Vizcaíno, F., Cogolludo, A. L., & Cortijo, J. (2013) · Thorax · doi:10.1136/thoraxjnl-2013-203408 · Cited by 61
Self-citationLate treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse model
Li, M., Abdollahi, A., Gröne, H., Lipson, K. E., Belka, C., & Huber, P. E. (2009) · Radiation Oncology · doi:10.1186/1748-717x-4-66 · Cited by 61
Keap1–Nrf2 pathway: A promising target towards lung cancer prevention and therapeutics
Tong, Y., Zhang, B., Fan, Y., & Lin, N. (2015) · Chronic Diseases and Translational Medicine · doi:10.1016/j.cdtm.2015.09.002 · Cited by 58
Nagashio, R., Ueda, J., Ryuge, S., Nakashima, H., Jiang, S., Kobayashi, M., Yanagita, K., Katono, K., Satoh, Y., Masuda, N., et al. (2015) · Scientific Reports · doi:10.1038/srep08649 · Cited by 56
Association between Variations in Cell Cycle Genes and Idiopathic Pulmonary Fibrosis
Korthagen, N. M., van Moorsel, C. H. M., Barlo, N. P., Kazemier, K. M., Ruven, H. J. T., & Grutters, J. C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030442 · Cited by 55
Takahashi, T., Munakata, M., Ohtsuka, Y., Nisihara, H., Nasuhara, Y., Kamachi, A., Dosaka‐Akita, H., Homma, Y., & Kawakami, Y. (2002) · Cancer · doi:10.1002/cncr.10708 · Cited by 54
Targeting Growth Factors in Lung Cancer
Hodkinson, P. S., MacKinnon, A. C., & Sethi, T. (2008) · CHEST Journal · doi:10.1378/chest.07-2680 · Cited by 52
Cancer and interstitial lung disease
Artinian, V., & Kvale, P. A. (2004) · Current Opinion in Pulmonary Medicine · doi:10.1097/00063198-200409000-00017 · Cited by 52
Masai, K., Tsuta, K., Motoi, N., Shiraishi, K., Furuta, K., Suzuki, S., Asakura, K., Nakagawa, K., Sakurai, H., WATANABE, S.-I. J., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.07.034 · Cited by 52
Artesunate ameliorates lung fibrosis via inhibiting the Notch signaling pathway
Liu, Y., Huang, G., Mo, B., & Wang, C. (2017) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2017.4573 · Cited by 52
Notch signaling and non-small cell lung cancer (Review)
Zou, B., Zhou, X., Lai, S., & Liu, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.7738 · Cited by 52
Genomic profiles of lung cancer associated with idiopathic pulmonary fibrosis
Hwang, J. A., Kim, D., Chun, S., Bae, S., Song, J. S., Kim, M. Y., Koo, H. J., Song, J. W., Kim, W. S., Lee, J. C., et al. (2017) · The Journal of Pathology · doi:10.1002/path.4978 · Cited by 49
Zhu, B., Ferry, C. H., Markell, L. K., Blazanin, N., Glick, A. B., Gonzalez, F. J., & Peters, J. M. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.551069 · Cited by 47
Mio, T., Nagai, S., Kitaichi, M., Kawatani, A., & Izumi, T. (1992) · CHEST Journal · doi:10.1378/chest.102.3.832 · Cited by 46
Kawasaki, H., Ogura, T., Yokose, T., Nagai, K., Nishiwaki, Y., & Esumi, H. (2001) · Human Pathology · doi:10.1053/hupa.2001.28246 · Cited by 46
An, J., Ying, X., Long, M., Zhang, G., Zhang, J., & Su, H. (2017) · Oncotarget · doi:10.18632/oncotarget.16837 · Cited by 46
“Scar-cinoma”: viewing the fibrotic lung mesenchymal cell in the context of cancer biology
Horowitz, J. C., Osterholzer, J. J., Marazioti, A., & Stathopoulos, G. T. (2016) · European Respiratory Journal · doi:10.1183/13993003.01201-2015 · Cited by 45
Xiao, H., Zhang, G., Liao, X., Li, X., Zhang, J., Lin, H., Chen, Z., & Zhang, X. (2018) · International Journal of Rheumatic Diseases · doi:10.1111/1756-185x.13247 · Cited by 44
Caliò, A., Lever, V., Rossi, A., Gilioli, E., Brunelli, M., Dubini, A., Tomassetti, S., Piciucchi, S., Nottegar, A., Rossi, G., et al. (2017) · Histopathology · doi:10.1111/his.13269 · Cited by 44
Differential epithelial expression of SHH and FOXF1 in usual and nonspecific interstitial pneumonia
Coon, D. R., Roberts, D. J., Loscertales, M., & Kradin, R. L. (2006) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2005.12.003 · Cited by 43
Zhang, X., Qin, X., Qin, C. Y., Yin, Y., Chen, Y., & Zhu, H. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1361-y · Cited by 42
Wang, P., Song, L., Ge, H., Jin, P.-L., Jiang, Y., Hu, W., & Geng, N. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s68773 · Cited by 41
Prevalence, risk factors and survival of lung cancer in the idiopathic pulmonary fibrosis
Lee, K. J., Chung, M. P., Kim, Y. W., Lee, J. H., Kim, K. S., Ryu, J., Lee, H. L., Park, S., Park, C., Uh, S.-T., et al. (2011) · Thoracic Cancer · doi:10.1111/j.1759-7714.2011.00107.x · Cited by 39
Xie, M., Wu, X.-J., Zhang, J.-J., & He, C.-S. (2015) · Oncotarget · doi:10.18632/oncotarget.5361 · Cited by 38
Airway Myofibroblasts and Their Relationship with Airway Myocytes and Fibroblasts
Singh, S. R., & Hall, I. P. (2007) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200706-070vs · Cited by 37
Pastuszak‐Lewandoska, D., Domańska-Senderowska, D., Antczak, A. J., Kordiak, J., Górski, P., Czarnecka, K. H., Migdalska‐Sęk, M., Nawrot, E., Kiszałkiewicz, J., & Brzeziańska‐Lasota, E. (2018) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-018-0355-7 · Cited by 33
Emerging therapeutic interventions for idiopathic pulmonary fibrosis
Chakraborty, S., Chopra, P., Ambi, S. V., Dastidar, S. G., & Ray, A. (2014) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2014.913569 · Cited by 29
Fibrocytes and the pathogenesis of diffuse parenchymal lung disease
Mehrad, B., & Strieter, R. M. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-s1-s22 · Cited by 29
Defective Autophagy in Fibroblasts May Contribute to Fibrogenesis in Autoimmune Processes
Principe, D. D., Vona, R., Giordani, L., Straface, E., & Giammarioli, A. M. (2011) · Current Pharmaceutical Design · doi:10.2174/138161211798357791 · Cited by 26
Development of Novel Agents for Idiopathic Pulmonary Fibrosis
O’Riordan, T. G., Smith, V., & Raghu, G. (2015) · CHEST Journal · doi:10.1378/chest.14-3218 · Cited by 26
Multiple roles of extracellular fibroblast growth factors in lung cancer cells
Suzuki, T., Yasuda, H., FUNAISHI, K., Arai, D., Ishioka, K., Ohgino, K., Tani, T., Hamamoto, J., Ohashi, A., Naoki, K., et al. (2014) · International Journal of Oncology · doi:10.3892/ijo.2014.2718 · Cited by 20
Germline mutations predisposing to non-small cell lung cancer
Clamon, G. H., Bossler, A., Hejleh, T. A., & Furqan, M. (2015) · Familial Cancer · doi:10.1007/s10689-015-9796-x · Cited by 16
Ye, G., Tan, N., Meng, C., Li, J., Li, J., Yan, M., Jin, T., & Chen, F. (2017) · Oncotarget · doi:10.18632/oncotarget.22329 · Cited by 16
MUC 1‐C drives myeloid leukaemogenesis and resistance to treatment by a survivin‐mediated mechanism
Stroopinsky, D., Rajabi, H. N., Nahas, M. R., Rosenblatt, J. M., Rahimian, M., Pyzer, A. R., Tagde, A., Kharbanda, A., Jain, S. S., Kufe, T., et al. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13662 · Cited by 15
Yang, J. D., Xu, T., Gomez, D. R., Jeter, M. D., Levy, L. B., Song, Y., Hahn, S. M., Liao, Z. X., & Yuan, X. (2017) · Translational Oncology · doi:10.1016/j.tranon.2016.12.009 · Cited by 14
From bad to worse: when lung cancer complicates idiopathic pulmonary fibrosis
Strock, S. B., Alder, J. K., & Kass, D. J. (2017) · The Journal of Pathology · doi:10.1002/path.5027 · Cited by 14
Lung Cancer in Patients with Severe Idiopathic Pulmonary Fibrosis: Critical Aspects
Bargagli, E., Bonti, V., Ferrari, K., Rosi, E., Bindi, A., Bartolucci, M., Moroni, C., & Voltolini, L. (2017) · In Vivo · doi:10.21873/invivo.11130 · Cited by 13
Ueda, T., Aokage, K., Nishikawa, H., Neri, S., Nakamura, H., Sugano, M., Tane, K., Miyoshi, T., Kojima, M., Fujii, S., et al. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2602-z · Cited by 11
Role of MUC1 in idiopathic pulmonary fibrosis: mechanistic insights
Ballester, B., Roger, I., Contreras, S., Montero, P., & Milara, J. (2017) · European Respiratory Journal · doi:10.1183/1393003.congress-2017.pa4889 · Cited by 2
Self-citation
Cited by
Oxidative Stress and Inflammation in Acute and Chronic Lung Injuries
Bezerra, F. S., Lanzetti, M., Nesi, R. T., Nagato, A. C., Silva, C. P. E., Kennedy-Feitosa, E., Melo, A. C., Cattani-Cavalieri, I., Porto, L. C., & Valenca, S. S. (2023) · Antioxidants · doi:10.3390/antiox12030548 · Cited by 336
Immune Checkpoint Inhibitor-Related Pneumonitis
Gomatou, G., Tzilas, V., Kotteas, E., Syrigos, K., & Bouros, D. (2020) · Respiration · doi:10.1159/000509941 · Cited by 75
The Hedgehog Signaling Pathway in Idiopathic Pulmonary Fibrosis: Resurrection Time
Effendi, W. I., & Nagano, T. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms23010171 · Cited by 59
Radon Biomonitoring and microRNA in Lung Cancer
Bersimbaev, R., Pulliero, A., Bulgakova, O., Kussainova, A., Aripova, A., & Izzotti, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062154 · Cited by 53
Luo, J., Zhang, T., Zhu, C., Sun, J., Zhu, W., Ai, W., Huang, X., & Wang, X. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15505 · Cited by 46
Metadata
- Authors
- Ballester, B., Milara, J., & Cortijo, J.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2019-01-30
- Volume
- 20
- Issue
- 3
- Pages
- 593
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2913356394
- Cited by
- 308
- References
- 244
- FWCI
- 22.07
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.